Vaccine Talks — Egyptian edition
About us

Vaccine
Talk

(Egyptian Edition)

"Everything you need to know about

vaccines in Egypt"

← Special Populations
HCP · Special populations

Vaccinations with Multiple Sclerosis

Evidence-based timing of non-live and live vaccines with MS disease-modifying therapies — synthesized from ECTRIMS/EAN 2023, NMSS, VA MS Centers of Excellence, and peer-reviewed clinical guidance.

Content added: JUNE 05, 2026

Last updated: JUNE 05, 2026

Introduction

Managing multiple sclerosis (MS) means balancing neurological health with the body's ability to fight everyday infections. Patients on disease-modifying therapy (DMT) or immunosuppressants often ask: Is vaccination safe? Will my medication make the vaccine fail? Do I need to delay treatment?

This guide synthesizes recommendations from the 2023 ECTRIMS/EAN consensus guidelines, the National Multiple Sclerosis Society (NMSS), the U.S. Department of Veterans Affairs (VA) MS Centers of Excellence, and peer-reviewed clinical data — organized for quick use in clinic.

The core safety rules of MS vaccinations

Before individual drug timing, four universal rules apply to every patient with MS:

  • Inactivated vaccines are entirely safe. Non-live vaccines (inactivated, recombinant, subunit, or mRNA) do not trigger MS onset and do not cause disease relapses.
  • Blunted response ≠ zero response. High-potency treatments may reduce antibody levels, but a reduced response still offers meaningful protection. Authorities strongly recommend vaccination anyway.
  • The relapse delay rule. Never vaccinate during an active MS relapse. If a flare occurs, delay all vaccines for 4–6 weeks from relapse onset, or until symptoms have stabilized.
  • The household FluMist warning. Household contacts should avoid live-attenuated nasal influenza vaccines (FluMist). Live virus can be shed for up to 1 week, posing accidental exposure risk if the patient is highly immunocompromised. Contacts should receive standard inactivated influenza vaccines instead.

1. Non-depleting therapies

Beta-interferons, teriflunomide, DMF, natalizumab

Includes: Beta-interferons (Avonex, Rebif, Plegridy), teriflunomide (Aubagio), dimethyl fumarate (DMF / Tecfidera), and natalizumab (Tysabri)

Non-live vaccines: Safe at any time. No need to pause, skip, or alter dosing. Patients typically mount a robust, normal immune response.

Live vaccines: Generally contraindicated while on treatment. If mandatory, administer at least 4–6 weeks before the first dose when starting therapy.

2. Anti-CD20 & anti-CD19 infusions

Ocrelizumab, ublituximab, rituximab

Includes: Ocrelizumab (Ocrevus), ublituximab (Briumvi), and rituximab

Non-live vaccines: Strictly timed windows. If already on therapy: vaccinate 3–6 months after the last infusion and at least 4–6 weeks before the next infusion. New patients: complete all non-live vaccines 2–4 weeks before starting the drug.

Live vaccines: Strictly contraindicated while on therapy. New patients: complete live vaccines at least 6 weeks before the first infusion. If already treated: wait >18 months (or until B-cell repopulation is confirmed on blood tests) before live vaccination.

3. Anti-CD20 subcutaneous injections

Ofatumumab (Kesimpta)

Includes: Ofatumumab (Kesimpta) — monthly self-injection with B-cell depletion

Non-live vaccines: Prefer completing all vaccinations before initiation. If already on therapy: vaccinate 4 weeks before the next scheduled monthly dose. New patients: complete non-live vaccines 2–4 weeks before starting.

Live vaccines: Strictly contraindicated while on treatment. If required before therapy, complete live vaccination at least 4 weeks before the first dose.

4. S1P modulators

Fingolimod, ponesimod, ozanimod

Includes: Fingolimod (Gilenya), ponesimod (Ponvory), and ozanimod (Zeposia)

Non-live vaccines: Safe during treatment, but expect a blunted antibody response. VA guidelines and clinical data warn: do not stop or pause the S1P modulator to improve vaccine response — this can trigger severe MS rebound relapse. New patients: complete vaccines 2–4 weeks before starting.

Live vaccines: Strictly contraindicated while on the drug. New patients: complete live vaccines at least 4 weeks before starting. After stopping, wait 1 month for drug clearance before live vaccination.

5. Cladribine (Mavenclad)

Short periodic oral courses

Includes: Cladribine (Mavenclad) — oral treatment in short courses that temporarily reduces T and B lymphocytes

Non-live vaccines: May be given any time after 4 weeks from completion of the last treatment course. If vaccination is needed immediately before a new course, delay starting the next Cladribine block by at least 2 weeks after the shot. Treatment-naïve patients: finish non-live vaccines 2–4 weeks before Day 1.

Live vaccines: Strictly contraindicated while on therapy. New patients: complete live vaccines at least 4 weeks before beginning Cladribine cycles.

6. Alemtuzumab (Lemtrada)

Intensive infusion therapy

Includes: Alemtuzumab (Lemtrada) — two annual infusion courses that fundamentally reset the immune system

Non-live vaccines: Strictly timed windows. Between annual courses: schedule non-live vaccinations approximately 3 months before the second scheduled course. New patients: complete non-live vaccines 2–4 weeks before starting treatment.

Live vaccines: Strictly contraindicated. New patients: live vaccines at least 6 weeks before the first infusion. After completing treatment courses: wait >3 months after stopping before live vaccination can be considered.

Timing vaccines after steroid treatments

Systemic high-dose corticosteroids (e.g. IV methylprednisolone / Solu-Medrol, or high-dose oral prednisone) are standard for acute MS relapses. Because steroids temporarily suppress immune response, adjust vaccine timing as follows:

  • Following a relapse pulse or high-dose course: If short-term pulse high-dose steroids were used for a relapse, or prednisone ≥20 mg/day for >14 days, delay all vaccines for 1 month after stopping steroids.
  • Short-term, low-dose courses: If steroids were <20 mg/day and lasted <14 days, vaccinate immediately after finishing the course.
  • Low-dose maintenance: If maintenance prednisone stays <20 mg/day, live vaccines can be given without pausing therapy.

High-priority vaccines for people with MS

Per NMSS, ECTRIMS, and VA guidance, prioritize these non-live immunizations to prevent severe viral complications:

  • Annual influenza & COVID-19 boosters: Strongly recommended for all patients. May be co-administered at the same visit.
  • Pneumococcal (pneumonia): Recommended for all patients starting or on immunosuppressive DMTs. NMSS highlights this especially for compromised respiratory function — including full-time wheelchair users or bed-bound patients.
  • RSV: Recommended for adults ≥75 years, and adults 60–74 who are immunocompromised due to MS therapies.
  • HPV (Gardasil-9): Recommended up to age 45. Ideally complete before starting a DMT, as immunosuppression can impair clearance of chronic HPV infection.

The strict VZV & shingles safety protocol

Before starting S1P modulators or Cladribine, run a VZV IgG antibody test before prescribing:

Scenario A — VZV seronegative (−)

  • No natural chickenpox immunity — high risk of dangerous viral replication on immunosuppressants.
  • Administer the Varicella (chickenpox) live vaccine: 2 doses, 4 weeks apart.
  • Delay starting MS medication for 4 weeks after the final Varicella dose.
  • Wait at least 8 weeks after Varicella vaccination before giving Shingrix.

Scenario B — VZV seropositive (+)

  • Existing immunity — cleared to start MS medication.
  • If age ≥19 and on immunosuppressive DMT: strongly encourage Shingrix (non-live recombinant shingles vaccine; 2 doses 2–6 months apart).

Critical note: Shingrix is non-live and highly effective against shingles, but it cannot substitute for primary Varicella vaccination when serology is negative.

References